ReviewFrontiers in oncology2026
Metabolic symbiosis and competition: the dual nature of TAM-tumor cell cross-talk in tumor progression.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer cells and tumor associated macrophages (TAMs) engage in a sophisticated metabolic symbiosis within the tumor microenvironment (TME), where reciprocal metabolite exchange drives immune evasion and malignant progression. This review posits that TAMs functional plasticity is not merely a consequence but a driver of tumor fitness, governed by extensive metabolic rewiring. We dissect the mechanistic underpinnings of this "metabolic dialogue," focusing on the convergence of glycolytic flux, the lactate shuttle, amino acid catabolism, lipid reprogramming, hypoxia-induced adaptations, and TCA cycle anaplerosis. Beyond delineating these pathways, we critically evaluate emerging therapeutic paradigms that target these metabolic nodes, advocating for precision interventions capable of disrupting this pro-tumorigenic alliance while restoring immune surveillance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.